Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Biosimilar-Reference'

Biosimilar-Reference published presentations and documents on DocSlides.

The generic and biosimilar
The generic and biosimilar
by alida-meadow
perspective. Warwick Smith. Director General BGMA...
U.S. Biosimilars: An Introduction
U.S. Biosimilars: An Introduction
by calandra-battersby
Disclaimers. :. By 2016, 7 of the top 10 pharmace...
PhAMA Position on Biosimilar Medicines
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
MODULE 8. Follow-on drugs: generic, biosimilar
MODULE 8. Follow-on drugs: generic, biosimilar
by alida-meadow
& non-biological similar medicinal products ....
  What is the value of Real-World Evidence for Biosimilars?
  What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
Application of Biosimilars in RA IN Clinical Practice:
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges.  . Introduction. Diff...
United Spinal Association
United Spinal Association
by alida-meadow
August, 2014. Biologics & Biosimilars: . An O...
Applying Biosimilars in Hematologic Cancers
Applying Biosimilars in Hematologic Cancers
by conchita-marotz
This program will include a discussion of off-lab...
Understanding Biologics Biologics and Biosimilars
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Biosimilars in the Real World
Biosimilars in the Real World
by liane-varnes
Introduction/Overview . PLANETRA Extension Study:...
Concurrent Session 1B
Concurrent Session 1B
by yoshiko-marsland
View . from the Life Sciences . Industry. Moderat...
Biosimilars in RA: A Blessing or a Curse?
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Is Australia ready for
Is Australia ready for
by liane-varnes
biosimilar. . ?. David Lim, Julie Hepworth, Lis...
Regulatory aspects and review
Regulatory aspects and review
by mary
of EMA authorized . biosimilars. Session “Biosim...
Challenges in Assessing Therapeutic Equivalence of
Challenges in Assessing Therapeutic Equivalence of
by thomas
Nanosimilars. Beat . Flühmann. Global Lead NBCD ....
1 Immunogenicity The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Prescription Drug Resource Center
Prescription Drug Resource Center
by roberts
Generic Drug Substitution Laws May 3 , 2019 Compi...
NEUPOGEN filgrastim
NEUPOGEN filgrastim
by gelbero
GRANIX (tbo - filgrastim), NIVESTYM (filgrastim -...
Medicare Part B Step Therapy Programs
Medicare Part B Step Therapy Programs
by elina
Page 1 of 10 UnitedHealthcare Medicare Advantag...
Improving Your Formulary and Denials Management
Improving Your Formulary and Denials Management
by trinity
Zinkeng Asonganyi, PharmD. Director of Pharmacy Se...
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
by anastasia
x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...
PSHP President’s Update
PSHP President’s Update
by myesha-ticknor
PSHP Annual Assembly. October 28, 2015. Matt Scol...
Biosimilars in emerging markets- regulatory and Commercial considerations
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Latin American Physician Perspectives on Biosimilars
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
National Pharmacy Practice
National Pharmacy Practice
by debby-jeon
Gene Dorr . Area Vice President, PBM Consulting. ...
PSHP President’s Update
PSHP President’s Update
by olivia-moreira
PSHP Annual Assembly. October 28, 2015. Matt Scol...
ASBM Biosimilars US Prescribers and Biosimilars Naming
ASBM Biosimilars US Prescribers and Biosimilars Naming
by min-jolicoeur
Kevin Olson, CEO. Industry Standard Research. Kev...
About OMICS Group OMICS Group International is an amalgamation of 
About OMICS Group OMICS Group International is an amalgamation of 
by sherrill-nordquist
Open Access publications.  and worldwide interna...
High-resolution SPR surrogate potency assay to facilitate comparability and biosimilar studies
High-resolution SPR surrogate potency assay to facilitate comparability and biosimilar studies
by test
Veronica Fridh, GE Healthcare, Uppsala, Sweden No...
Biosimilars 2012 AIPLA Webinar
Biosimilars 2012 AIPLA Webinar
by stefany-barnette
September 25, 2012. 1. Denise. Kettelberger, PhD...
Conference Series LLC
Conference Series LLC
by alida-meadow
Conferences. Conference Series LLC . is a pioneer...
FDA Approves First Biosimilar Sandozs Zarxio By Jennif
FDA Approves First Biosimilar Sandozs Zarxio By Jennif
by pamella-moone
Dienes Maria E Doukas Christopher J Betti PhD ...
Biosimilar biological productEvaluation by the FDA
Biosimilar biological productEvaluation by the FDA
by alida-meadow
oducts used to diagnose, prevent, of diseases and ...
A QUM partnership approach to regulating
A QUM partnership approach to regulating
by liane-varnes
biosimilars. in Australia. David Lim, Evan Siege...